Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: Results from the PRACMA study

Macitentan is a dual endothelin receptor antagonist indicated for the long-term treatment of pulmonary arterial hypertension (PAH). We evaluated the change over time in REVEAL risk score in incident and prevalent patients receiving macitentan for the first time.